Black Diamond Therapeutics, Inc.
BDTX
$3.05
$0.113.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -57.17% | -25.92% | -45.51% | -33.62% | 39.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.36% | -23.59% | -26.49% | -24.50% | 10.47% |
| Operating Income | 39.36% | 369.34% | 26.49% | 24.50% | -10.47% |
| Income Before Tax | 46.95% | 410.24% | 17.64% | 32.38% | -3.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.95% | 410.24% | 17.64% | 32.38% | -3.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.95% | 410.24% | 17.64% | 32.38% | -3.95% |
| EBIT | 39.36% | 369.34% | 26.49% | 24.50% | -10.47% |
| EBITDA | 39.51% | 370.92% | 26.60% | 24.49% | -10.67% |
| EPS Basic | 48.50% | 383.66% | 24.87% | 39.04% | 31.17% |
| Normalized Basic EPS | 48.49% | 367.89% | 37.88% | 39.04% | 31.18% |
| EPS Diluted | 47.37% | 378.57% | 24.87% | 39.04% | 31.17% |
| Normalized Diluted EPS | 48.49% | 363.18% | 37.88% | 39.04% | 31.18% |
| Average Basic Shares Outstanding | 2.99% | 9.37% | 9.63% | 10.92% | 51.04% |
| Average Diluted Shares Outstanding | 2.99% | 11.32% | 9.63% | 10.92% | 51.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |